SCHEDULE 13G/A: Vanguard Group Amends Stake in Insmed Inc, Reports Over 10% Beneficial Ownership

The Vanguard Group has filed an amended Schedule 13G, disclosing a 10.18% beneficial ownership stake in Insmed Inc as of December 31, 2024.

Summary

• The Vanguard Group, a major investment management company, has filed an Amendment No. 10 to its Schedule 13G for Insmed Inc.
• As of December 31, 2024, The Vanguard Group beneficially owns an aggregate of 18,218,973 shares of Insmed Inc's Common Stock.
• This ownership represents 10.18% of the class of securities.
• The Vanguard Group holds sole voting power over 0 shares, shared voting power over 323,966 shares, sole dispositive power over 17,689,773 shares, and shared dispositive power over 529,200 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Insmed Inc.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership filing (Schedule 13G Amendment), which is purely factual and does not convey positive or negative sentiment regarding the issuer's performance or outlook. It simply reports a passive ownership stake.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by The Vanguard Group, one of the world's largest investment management companies, indicating its passive ownership stake in Insmed Inc, a biopharmaceutical company. Such filings are common for large institutional investors that hold significant, but non-controlling, positions across a broad portfolio of public companies.

Stakeholder Impact

• The filing indicates a significant passive ownership stake by The Vanguard Group, which may provide stability to the shareholder base of Insmed Inc.

Key Dates

Keywords

Insmed Inc, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, pharmaceutical, biotechnology